Travere reports preliminary Q4 2023 net product sales ~$40M, FILSPARI sales $15M; cash $567M

Travere Therapeutics, Inc.

2023-FY EPS reported -$1.50 revenue$145,238,000

Preliminary Q4 2023 net product sales from continuing ops ~$40M; FY 2023 ~$128M.
FILSPARI net sales Q4 ~$15M (launch-to-date ~$30M); 459 new patient start forms in Q4.
Cash, cash equivalents & marketable securities ~$567M; expected to fund operations into 2028.
sNDA for full FILSPARI approval in IgAN on track for Q1 2024; CHMP opinion also expected Q1 2024.
Pivotal Phase 3 HARMONY study for pegtibatinase in HCU initiated; topline results expected in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Travere Therapeutics, Inc. reported fiscal year 2023 results: revenue approximately $128 million.

Period: fiscal year 2023
Revenue: approximately $128 million
Result: preliminary results

Exact text from the filing

For the fiscal year 2023, the Company expects net product sales from continuing operations to be approximately $128 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Travere Therapeutics, Inc. reported fourth quarter of 2023 results: revenue $15 million.

Period: fourth quarter of 2023
Revenue: $15 million
Result: preliminary results

Exact text from the filing

the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Travere Therapeutics, Inc. reported fourth quarter of 2023 results: revenue $15 million.

Period: fourth quarter of 2023
Revenue: $15 million
Result: preliminary results

Exact text from the filing

Preliminary net product sales of FILSPARI in the fourth quarter of 2023 were $15 million

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-003866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.